Adjuvant Radiotherapy Reduces Atypical Meningioma Recurrence Risk

A randomized controlled trial (ROAM/EORTC-1308), published in The Lancet, found that adjuvant radiotherapy significantly lowers the recurrence risk for patients with WHO grade 2 atypical meningioma after complete surgical removal. This landmark study provides clear evidence expected to reshape global standard care for this aggressive brain tumor, where postoperative irradiation practices previously varied.